Study A3921133 is a recently completed, open-label, endpoint-driven study evaluating the safety of tofacitinib 5 and 10 mg BID compared with tumor necrosis factor inhibitors (TNFi) in patients with RA. The gene discussed is TNF; the disease is rheumatoid arthritis.